Amphotericin B-loaded nanoparticles for local treatment of cutaneous leishmaniasis
- 84 Downloads
Cutaneous leishmaniasis (CL) is an infectious, parasitic disease caused by the protozoan Leishmania. Amphotericin B (AMB) is a macrolide polyene antibiotic presenting potent antifungal and antileishmanial activity, but due to poor water solubility at physiological pH, side effects, and toxicity, its therapeutic efficiency is limited. In the present study, poly(lactic-co-glycolic acid) (PLGA) nanoparticles (NPs) loaded with AMB were generated to reduce drug toxicity and facilitate localized delivery over a prolonged time. AMB NPs were characterized for particle size, zeta potential, polydispersity index, and degree of aggregation. In vitro assessments demonstrated its sustained activity against Leishmania major promastigotes and parasite-infected macrophages. A single intralesional administration to infected BALB/c mice revealed that AMB NPs were more effective than AMB deoxycholate in terms of reducing lesion area. Taken together, these findings suggest that AMB NPs improve AMB delivery and can be used for local treatment of CL.
KeywordsAmphotericin B Nanoparticles Sustained release Cutaneous leishmaniasis Topical therapy
This research was funded by the GIP program of the Deutsche Forschungsgemeinschaft (DFG) German Research Foundation. EZ wish to acknowledge the financial support of the RBNI-The Russell Berrie Nanotechnology Institute at the Technion. CLJ holds the Michael and Penny Feiwel Chair of Dermatology.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
- 7.Mbongo N, Loiseau PM. Billion MA, Robert-Gero M. mechanism of amphotericin B resistance in Leishmania donovani promastigotes. Antimicrob Agents Chemother. 1998;42(2):352–7.Google Scholar
- 9.Escobar P, Matu S, Marques C, Croft SL. Sensitivities of Leishmania species to hexadecylphosphocholine (miltefosine), ET-18-OCH(3) (edelfosine) and amphotericin B. Acta Trop. 2002;81(2):151–7.Google Scholar
- 10.Yu BG, Okano T, Kataoka K, Sardari S, Kwon GS. In vitro dissociation of antifungal efficacy and toxicity for amphotericin B-loaded poly(ethylene oxide)-block-poly(beta benzyl L aspartate) micelles. J Control Release. 1998;56(1–3):285–91.Google Scholar
- 11.Wong-Beringer A, Jacobs RA, Guglielmo BJ. Lipid formulations of amphotericin B: clinical efficacy and toxicities. Clin Infect Dis. 1998;27(3):603–18.Google Scholar
- 12.Espuelas MS, Legrand P, Irache JM, Gamazo C, Orecchioni AM, Devissaguet JP, et al. Poly(e-caprolacton) nanospheres as an alternative way to reduce amphotericin B toxicity. Int J Pharm. 1997;158(1):19–27.Google Scholar
- 16.Reis CP, Neufeld RJ, Ribeiro AJ, Veiga F. Nanoencapsulation I. methods for preparation of drug-loaded polymeric nanoparticles. Nanomedicine. 2006;2(1):8–21.Google Scholar
- 17.Panyam J, Labhasetwar V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev. 2003;55(3):329–47.Google Scholar
- 21.Kapoor DN, Bhatia A, Kaur R, Sharma R, Kaur G, Dhawan S. PLGA: a unique polymer for drug delivery. Ther Deliv. 2015;6(1):41–58.Google Scholar
- 22.Makadia HK, Siegel SJ. Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier. Polymers. 2011;3(3):1377–97.Google Scholar
- 23.Uhrich KE, Cannizzaro SM, Langer RS, Shakesheff KM. Polymeric systems for controlled drug release. Chem Rev. 1999;99(11):3181–98.Google Scholar
- 24.von Burkersroda F, Schedl L, Gopferich A. Why degradable polymers undergo surface erosion or bulk erosion. Biomaterials. 2002;23(21):4221–31.Google Scholar
- 25.Palma E, Pasqua A, Gagliardi A, Britti D, Fresta M, Cosco D. Antileishmanial activity of amphotericin B-loaded-PLGA nanoparticles: an overview. Materials 2018;11(7). doi: https://doi.org/10.3390/ma11071167.
- 32.Haavikko R, Nasereddin A, Sacerdoti-Sierra N, Kopelyanskiy D, Alakurtti S, Tikka M, et al. Heterocycle-fused lupane triterpenoids inhibit Leishmania donovani amastigotes. MedChemComm. 2014;5(4):445–51.Google Scholar
- 33.Fessi H, Puisieux F, Devissaguet JP, Ammoury N, Benita S. Nanocapsule formation by interfacial polymer deposition following solvent displacement. Int J Pharm. 1989;55(1):R1–4.Google Scholar
- 34.Van de Ven H, Paulussen C, Feijens PB, Matheeussen A, Rombaut P, Kayaert P, et al. PLGA nanoparticles and nanosuspensions with amphotericin B: potent in vitro and in vivo alternatives to Fungizone and AmBisome. J Control Release. 2012;161(3):795–803. https://doi.org/10.1016/j.jconrel.2012.05.037. Google Scholar
- 35.Peppas NA. Analysis of Fickian and non-Fickian drug release from polymers. Pharm Acta Helv. 1985;60(4):110–1.Google Scholar
- 36.Van de Ven H, Paulussen C, Feijens P, Matheeussen A, Rombaut P, Kayaert P, et al. PLGA nanoparticles and nanosuspensions with amphotericin B: potent in vitro and in vivo alternatives to Fungizone and AmBisome. J Control Release. 2012;161(3):795–803.Google Scholar
- 37.Carraro TCMM, Khalil NM, Mainardes RM. Amphotericin B-loaded polymeric nanoparticles: formulation optimization by factorial design. Pharm Dev Technol. 2016;21(2):140–6.Google Scholar
- 38.Nahar M, Mishra D, Dubey V, Jain N, editors. Development of amphotericin b loaded PLGA nanoparticles for effective treatment of visceral leishmaniasis. 13th International Conference on Biomedical Engineering; 2009: SpringerGoogle Scholar
- 39.Barwicz J, Christian S, Gruda I. Effects of the aggregation state of amphotericin B on its toxicity to mice. Antimicrob Agents Chemother. 1992;36(10):2310–5.Google Scholar
- 42.Tsuchiya S, Kobayashi Y, Goto Y, Okumura H, Nakae S, Konno T, et al. Induction of maturation in cultured human monocytic leukemia cells by a phorbol diester. Cancer Res. 1982;42(4):1530–6.Google Scholar
- 49.Yardley V, Croft SL. A comparison of the activities of three amphotericin B lipid formulations against experimental visceral and cutaneous leishmaniasis. Int J Antimicrob Agents. 2000;13(4):243–8.Google Scholar
- 50.de Carvalho RF, Ribeiro IF, Miranda-Vilela AL, de Souza Filho J, Martins OP, Cintra e Silva Dde O, et al. Leishmanicidal activity of amphotericin B encapsulated in PLGA–DMSA nanoparticles to treat cutaneous leishmaniasis in C57BL/6 mice. Exp Parasitol. 2013;135(2):217–22.Google Scholar